Brief: Cymabay Therapeutics Announces Collaboration With Kaken Pharmaceutical To Develop And Commercialize Seladelpar In Japan For Primary Biliary Cholangitis
08/01/2023 17:02
Jan 8 (Reuters) - Cymabay Therapeutics Inc CBAY.O :
* CYMABAY THERAPEUTICS ANNOUNCES COLLABORATION WITH KAKEN
PHARMACEUTICAL CO., LTD. TO DEVELOP AND COMMERCIALIZE SELADELPAR
IN JAPAN FOR PRIMARY BILIARY CHOLANGITIS
* BRINGS IN APPROXIMATELY $34.0 MILLION UPFRONT PAYMENT
* KAKEN WILL BE RESPONSIBLE FOR DEVELOPMENT, REGULATORY
APPROVAL
AND COMMERCIALIZATION OF SELADELPAR IN JAPAN.
Source text for Eikon: ID:nGNX5Z2pTr
Further company coverage: CBAY.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on CymaBay Therapeutics
See all newsBrief: CymaBay Says EMA Accepted For Review The Marketing Authorization Application For Seladelpar
U.S. RESEARCH ROUNDUP-Bruker Corp, Cymabay Therapeutics, SSR Mining
U.S. RESEARCH ROUNDUP-An2 Therapeutics, Par Technology, Trimble
U.S. STOCKS ON THE MOVE-Perpetua Resources, Nvidia, SiriusXM
U.S. STOCKS ON THE MOVE-Lowe's, Bit Digital Snap